dc.contributor.author | Wang, Alex Z. | |
dc.contributor.author | Lebastchi, Amir H. | |
dc.contributor.author | O'Connor, Luke P. | |
dc.contributor.author | Ahdoot, Michael | |
dc.contributor.author | Mehralivand, Sherif | |
dc.contributor.author | Yerram, Nitin | |
dc.contributor.author | Taneja, Samir S. | |
dc.contributor.author | George, Arvin K. | |
dc.contributor.author | Sanchez-Salas, Rafael | |
dc.contributor.author | Ward, John F. | |
dc.contributor.author | del Pilar Laguna Pes, Maria | |
dc.contributor.author | de la Rosette, Jean J. M. C. H. | |
dc.contributor.author | Pinto, Peter A. | |
dc.date.accessioned | 2021-10-15T09:22:58Z | |
dc.date.available | 2021-10-15T09:22:58Z | |
dc.date.issued | 2021 | en_US |
dc.identifier.citation | Wang, A. Z., Lebastchi, A. H., O'Connor, L. P., Ahdoot, M., Mehralivand, S., Yerram, N. ... Pinto, P. A. (2021). Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: Current perspective and ongoing trials. World Journal of Urology, 39(3), 729-739. https://dx.doi.org/10.1007/s00345-020-03525-0 | en_US |
dc.identifier.issn | 0724-4983 | |
dc.identifier.issn | 1433-8726 | |
dc.identifier.uri | https://dx.doi.org/10.1007/s00345-020-03525-0 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/8457 | |
dc.description.abstract | Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical "middle ground" in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy. | en_US |
dc.description.sponsorship | United States Department of Health & Human Services National Institutes of Health (NIH) - USA ; Doris Duke Charitable Foundation (DDCF) ; Roche Holding ; Genentech ; American Association for Dental Research ; Colgate-Palmolive Company | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Focal Therapy | en_US |
dc.subject | MRI | en_US |
dc.subject | Prostate Cancer | en_US |
dc.title | Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: Current perspective and ongoing trials | en_US |
dc.type | article | en_US |
dc.relation.ispartof | World Journal of Urology | en_US |
dc.department | İstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0003-0906-4417 | en_US |
dc.authorid | 0000-0002-6308-1763 | en_US |
dc.identifier.volume | 39 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 729 | en_US |
dc.identifier.endpage | 739 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1007/s00345-020-03525-0 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.scopusquality | Q1 | en_US |